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Background: There are limited data regarding the benefit of cardiac resynchronization therapy with a defibrillator (CRT-D) in heart failure (HF) 
patients who develop atrial tachyarrhytmias (AT). We aimed to investigate the effect of AT on HF or death in CRT-D vs. implantable cardioverter 
defibrillator (ICD) treatment in patients with mild HF enrolled in MADIT-CRT.
methods: The benefit of CRT-D, in reducing the risk of HF or death in MADIT-CRT, was evaluated by the presence of a history of AT at baseline and 
time-dependent development of AT during the trial. Arrhythmias were assessed using adjudicated device interrogations.
results: The overall beneficial effect of CRT-D vs. ICD on the risk of HF or death was not significantly different between patients with or without a 
history of AT (HR = 0.71 and 0.59, respectively; p for interaction=0.47) Among patients who developed AT during the trial, CRT-D was associated with 
a significant 51% reduction in the risk of HF or death compared with ICD-only therapy (HR=0.49, p=0.01), similar to the effect of the device among 
patients who did not develop AT (HR=0.62; p-value for AT-by-treatment interaction = 0.50) (Figure). Consistent results were shown when the benefit 
of CRT-D was assessed among patients who developed in-trial paroxysmal atrial fibrillation/flutter (HR=0.39; p=0.037).
conclusions: In MADIT-CRT, the clinical benefit of cardiac resynchronization therapy was not attenuated following the development of AT. 
